Device Trial Radar · NCT02593149
Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
Last checked: Nov 20, 2026Latest source record: Feb 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,902
Actual
Start
Nov 2015
Primary completion
Nov 2016
Study completion Nov 2016
Sponsor
- Lead sponsor
- Pursuit Vascular, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Davita Clinical Research
- First posted
- Oct 30, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess blood stream infections in participants using two FDA-cleared devices: ClearGuard HD end caps compared to the Tego® connector with the CurosTM for Tego disinfecting port protector.
Conditions
- End Stage Renal Disease (ESRD)
Interventions
ClearGuard HD End CapDevice
The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
Primary outcomes
What the sponsor says the trial is designed to measure.
- Positive Blood Cultures (PBC's) Per 1,000 Central Venous Catheter (CVC)-DaysTime frame: Through the 13-month intervention period.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
DaVita Clinical Research
Minneapolis, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.